To investigate racial differences in tumor burden (cancer volume, cancer percentage and cancer to PSA ratios) in a large cohort of men undergoing radical prostatectomy (RP). METHODS: Demographic, clinical and pathological data of patients undergoing RP between 1993-2010 were reviewed and compared between African-American (AA) and non African-American (nAA) men. Further assessments of pathological tumor burden (estimated tumor volume, percent of cancer involvement, and estimated tumor volume/PSA ratios) were performed across Gleason score categories. RESULTS: Of 4157 patients in the analysis, 604 (14.5%) were AA. Overall, AA patients were younger, had higher Gleason scores, PSA levels and incidence of palpable disease (all Po0.001). Despite comparable prostate weights (39.4 vs. 39.6 g), AA men had higher percent cancer involvement and estimated tumor volume (all Po0.001) but similar estimated tumor volume/PSA ratios (P40.05). When stratified by Gleason scores, prostate weights were comparable; however, estimated tumor volume, percent cancer involvement and estimated tumor volume/PSA ratios were higher in AA men with low grade (p6) prostate cancer (PCa), similar in intermediate grade (7) (8) and lower in high grade (9-10) PCa compared to nAA men. CONCLUSIONS: In this large series, AA patients had higher disease burden (estimated tumor volume, percent cancer involvement, estimated tumor volume/PSA ratios) compared to nAA but this association was especially pronounced in low grade (Gleason p6) cancers. These data depict a complex picture of relations between race and tumor burden across the spectrum of PCa aggressiveness. Further investigation is warranted to understand the mechanisms of racial disparities in PCa.
INTRODUCTION
Racial differences in the features and natural history of prostate cancer (PCa) are well documented, 1, 2 with African-Americans (AA) at higher risk of being diagnosed with PCa, having more aggressive disease and higher likelihood of cancer-specific death. 1, 2 However, whether these may be accounted for by differences in socioeconomic status or in tumor biology is less clear. Likely no single factor (i.e. genetic factors, lifestyle, obesity, socioeconomic status, etc.) can explain the observed racial differences in PCa by itself. In the era of PSA screening characterized by early detection of PCa at lower stage and grade, AA men remain at higher risk of aggressive disease compared to other ethnical groups while potential biological, pathological and socioeconomic explanations of this finding remain in question. 2 Herein we investigated the association between tumor burden (cancer percentage, estimated tumor volume and tumor volume to PSA ratios) on final pathology and race in a large cohort of men undergoing radical prostatectomy in a tertiary referral center.
MATERIALS AND METHODS
After approval from the Institutional Review Board, we retrieved data on patients undergoing radical prostatectomy for clinically localized PCa at Duke University Medical Center between 1993 and 2010. Demographic and clinical variables were collected including age, race (AA versus non African-American (nAA)), pre-operative digital rectal examination status (palpable versus non-palpable disease) and pre-operative PSA levels.
Radical prostatectomy specimens harvested in the operating room were inked, weighed and fixed overnight. Apex and bladder neck margins were shaved for margin status analysis. The remaining prostate was then sectioned perpendicular to the rectal surface at 3-4 mm intervals and submitted entirely for microscopic evaluation. Gleason scores and cancer percentage were recorded based on pathology reports. Cancer percentage on each slide was estimated as percent of the slide involved by cancer. Percent of tumor involvement was estimated by averaging the results from all slides analyzed. Estimated tumor volume was calculated multiplying prostate specimen weight by percent cancer involvement assuming 1 g ¼ 1 cc. The estimated tumor volume/PSA ratio was calculated by dividing tumor volume by the preoperative PSA level. Gleason score was categorized using six groups: o6, 6, 3 þ 4, 4 þ 3, 8 and 9-10. Pathological stage was dichotomized into localized (T2a-c) and nonlocalized (XT3) PCa.
Demographic, clinical and pathological characteristics were compared between AA and nAA patients across Gleason score categories. In each Gleason score category, percent cancer involvement, prostate weight, PSA, estimated tumor volume and tumor volume to PSA ratios were compared between AA and nAA. Comparisons were performed using rank sum and chi-squared tests for continuous and categorical variables, respectively.
Statistical analyses were performed using R v2.11 (The R Foundation for Statistical Computing, Vienna, Austria) using Hmisc and Design packages. All tests were 2-tailed; P values o0.05 were considered statistically significant.
RESULTS
A total of 4157 patients underwent radical prostatectomy between 1993 and 2010 at our institution for clinically localized PCa. Of those, 604 (14.5%) were AA men. Pathological Gleason score distribution for all men was as follows: o6 (467; 11%), 6 (1379; 33%), 3 þ 4 (1329; 32%), 4 þ 3 (516; 12%), 8 (219; 5%) and 9-10 (247; 6%). AA men were younger at time of surgery, had higher Gleason scores, higher incidence of palpable disease (4% vs. 2%, Po0.001), as well as higher PSA levels (6.4 vs. 5.9 ng/ml, Po0.001), percent cancer involvement (Po0.001) and estimated tumor volume (4.4 vs. 4.0 cc, Po0.001), despite no significant differences in prostate weights (39.4 vs. 39.6 g, P ¼ 0.574; Table 1 ).
When stratified by Gleason scores, AA patients with pathological Gleason scores o6 and 6 showed higher percent cancer involvement and higher estimated tumor volume, although prostate weights were comparable ( Table 2 ). Tumor volume and cancer involvement were comparable between AA and nAA with Gleason scores 7 (3 þ 4 and 4 þ 3) and 8; tumor volume/PSA ratios were lower in nAA but the difference was significant only in Gleason 4 þ 3 cancers. However, in Gleason score 9-10 cancers, estimated tumor volume, percent cancer involvement and tumor volume/PSA ratios were significantly lower in AA men compared to nAA men with prostate cancer (P ¼ 0.009, P ¼ 0.030 and P ¼ 0.033, respectively). Preoperative PSA values were generally higher in AA patients across all Gleason score categories. The estimated tumor volume/PSA ratios tended to be higher in AA with low grade (Gleason score p6) PCa. However, in men with higher grade tumors, the association was inverse, whereby AA men exhibited smaller tumor volume to PSA ratios when compared to nAA men.
DISCUSSION
Although racial differences in natural history, prognosis and biology of PCa seem to be ascertained, 1, 2 it is unclear as to what these differences can be attributed. Likely, no single factor (i.e. genetic factors, lifestyle, obesity, socioeconomic status, etc.) is independently responsible for the observed variability. There is also no agreement on which specific clinical and pathological differences can be attributed to race. Specifically, in the current era of PSA screening that brought about higher detection rates of early PCa, characterized by low stage and low grade disease, AA men are still at higher risk of more aggressive disease compared to men from nAA ethnic backgrounds. 2 In this study, we found that AA men undergoing radical prostatectomy had higher tumor volume compared to nAA men and this difference was accentuated among low Gleason score (i.e. p6) cancers. In intermediate Gleason score cancers (7-8) tumor burden was comparable, whereas in high Gleason score cancers (9-10) AA men showed lower tumor volumes compared to nAA men.
Racial differences in PCa biology and PCa-specific outcomes after surgical treatment have been debated for a long time. Higher PCa incidence and higher PCa mortality among AA men are wellestablished. 1 However, whether racial background plays an independent role in RP outcomes remains controversial. In fact, while several studies argued an independent prognostic role for race, [3] [4] [5] [6] others have argued the contrary. [7] [8] [9] Similarly, differences in clinical and pathological characteristics of PCa have been studied, but the results are equivocal. While some authors report that AA patients had higher PSA levels at presentation, 7,9,10 higher incidence of non-organ-confined disease and higher rates of adverse pathological features, 3, 11, 12 these findings are not shared by other authors that report no differences that can be attributed to race. 7, 8, 10 In the present cohort, we demonstrate evident differences in baseline characteristics according to race. Overall, AA men were younger, had higher PSA levels at diagnosis and higher incidence of palpable disease on digital rectal exams. These findings suggest that at the time of presentation, AA men may have less favorable clinical features supporting the claim that AA men may have more aggressive PCa.
There were significant differences in several pathological parameters between AA and nAA patients in this study. First, we found AA men to have higher pathological Gleason scores. However, the rates of organ-confined disease were comparable between the groups. Despite comparable prostate weights, AA men had higher cancer burden -percent tumor involvement and estimated tumor volume were significantly higher compared to nAA patients. Several studies examined the differences in tumor volume based on racial background. Pettaway et al. 12 analyzed pathological features of 40 radical prostatectomy specimens from AA patients matched to a cohort of 148 nAA men. The authors found a significantly higher proportion of adverse pathological features in AA patients but no differences were detected in tumor volume or prostate weight. In a later study, Resnick and colleagues 8 reported on a cohort of 91 AA patients with low risk PCa and found no significant differences in estimated tumor volume, along with comparable clinical and pathological features (PSA, age, Gleason scores, seminal vesicle invasion and extracapsular extension). Contrary to these findings, Sanchez-Ortiz et al.
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who matched 37 AA and 35 Caucasian patients, found the former to have more adverse pathological features as well as higher tumor volume and higher tumor volume to PSA ratios. Differences in tumor volume were investigated further by Higher tumor burden in black men with prostate cancer M Tsivian et al
Powell et al. 13 who analyzed an autopsy prostatectomy series and found higher PCa volume and more extensive high grade prostatic intraepithelial neoplasia in AA men with subclinical prostate cancer. The study by Powell et al. supports the theory that PCa growth is more rapid and transformation from latent to aggressive PCa happens earlier in AA men. Despite evidence that pathological features, and specifically tumor volume, may differ by race, the range of these differences has not been previously explored.
In the present study we stratified our cohort by Gleason scores as this has been shown to be a good indicator of biological aggressiveness of PCa. 14, 15 Despite comparable prostate weights, AA men showed higher estimated tumor volume and higher percent cancer involvement compared to nAA men; these differences were particularly pronounced at lower Gleason scores (p6) whereas at high Gleason scores (9-10) tumor volume and percent cancer involvement in AA men was lower. These complex relationships between race and tumor volume may explain the conflicting results in the literature with regards to race and tumor volume. In fact, in the autopsy series by Powell et al. 13 Gleason 6 or less disease was reported in the vast majority of specimens. Moreover, tumor volume to PSA ratios similarly showed a composite relation with race when stratified by PCa grade. In Gleason score o6 tumors, AA men tended to have higher tumor volume/ PSA ratios whereas in tumors with higher Gleason scores this association was inverse. Therefore, in AA patients, low Gleason score tumors tend to be larger. However, in intermediate/high Gleason score cancers this association is reversed and AA men exhibited lower tumor volumes and less cancer tissue per unit of PSA. This biological gradient across different grades of PCa warrants further investigation. This study is not void of limitations. Despite representing the largest cohort to date to report on this topic, it is a retrospective analysis and inherent potential for biases should be considered. Furthermore, this single center study will require validation in other cohorts. In addition, we could not compare tumor characteristics of men undergoing non-surgical PCa management as these men do not benefit from histopathological analysis of a whole prostate specimen. Moreover, we could not analyze potential differences in other racial groups due to subgroup sample size limitations. Finally, the composition of the study population in the present study may be affected by referral patterns that are expected in any tertiary center. Thus, validation in other clinical settings such as in equal-access hospitals should be performed. 16 Higher tumor burden in black men with prostate cancer M Tsivian et al
Racial differences in tumor volume and cancer percentage that were observed in this study may find a potential explanation in basic science. Higher androgen receptor protein expression in both benign and malignant prostate tissue as well as higher expression of sex-hormones-binding globulin 17 in AA men were reported. Similarly, genetic differences in the expression of androgen metabolism pathway enzymes (e.g. CY3A4) were demonstrated 18 and may, at least in part, account for the observed racial differences. However, it remains hypothetical whether the androgen metabolism pathway can explain the grade-related differences in tumor burden, thus further research is needed. PCa grade-related racial differences have been suggested in a study examining nucleic acid ploidy and proliferation of PCa whereby specimens from AA men, contrary to those of Caucasians, did not show any significant shift towards aneuploidy at higher (7-10) compared to lower (4-6) Gleason scores; 19 in fact, aneuploidy cancers were twice as frequent in white men with high grade PCa. Overall, these data suggest the existence of racial differences in PCa biology and their complex variability across tumor grades that require further understanding.
CONCLUSIONS
In this largest reported single center cohort we confirmed the existence of racial differences in presentation, clinical and pathological features of PCa. Focusing on tumor volume, we submit that AA men have higher disease burden (estimated tumor volume, tumor volume to PSA ratios) but this association is especially pronounced in low grade (Gleason scores p6) cancers. In high grade (Gleason 9-10) cancers AA men appeared to have lower tumor burdens. These data depict a complex series of relations between race and tumor burden across the spectrum of PCa aggressiveness. Further investigation is warranted to understand the mechanisms of racial disparities in PCa.
